Company
Ocular Therapeutix
NASDAQ:OCUL
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology.
6 stories
Ocular Therapeutix positive on new glaucoma treatment despite disappointing study results
Results showed that recent trials did not significantly reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension
US FDA to review Ocular Therapeutix’s resubmitted NDA for eye-pain drug Dextenza
The Massachusetts-based biotech’s Dextenza has completed Phase 3 evaluation for the treatment of pain, inflammation after eye surgery
US shares end higher after Yellen relief and oil gains
US shares ended higher, with small caps at levels not seen since 2015, after Federal Reserve Chairman Janet Yellen talked up the economy while dousing expectations of an immediate rate hike later this month and oil prices advanced
US shares upbeat after Yellen comments but pharma stocks suffer
US stocks remained firm at midsession on Monday after a positive tone on growth from Federal Reserve Chairman Janet Yellen and buoyant oil prices, while pharma stocks were weighed down after a flurry of clinical trial results
Archive
Ocular Therapeutix shares soar 61% on FDA news
Shares of Ocular Therapeutix soar 61% following a positive meeting with the US Food and Drug Administration and news of Phase 3 trial